Effect of Cichorium Intybus seed on treatment of nonalcoholic fatty liver

Evaluation of the effects of Cichorium intybus seed on treatment of nonalcoholic fatty liver disease,a randomized double_blind clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016061228411N1

Enrollment

Registered

2017-05-31

Start date

2017-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Cichorium intybus seed syrup,8cc bid. Intervention 2: Control group: standardized placebo 8 cc bid.

Treatment - Drugs

Placebo

Intervention group: Cichorium intybus seed syrup,8cc bid

Control group: standardized placebo 8 cc bid

Eligibility

Sex/Gender

All

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: sign the consent form? age between 20-45 years? BMI between 25-35?Ultrasound evidence confirm fatty liver disease? ALT level: more than 60 for men and 38 for women? negative pregnancy test? No breastfeeding? No alcohol consumption? non diabetes , kidney disease(Cr more than 1.5), hypothyroidism? hyperthyroidism? acute and chronic liver diseases? malignancy? non hepatotoxic drug consumption since 6 months ago? no allergy to Cichorium intybus. Exclusion Criteria: positive pregnancy test? allergy to Cichorium intybus? no tendency to continue the program.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: photometric.;AST. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: photometric.;FBS. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: Fasting blood glucose concentrations.;Triglisirid. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;Cholestrol. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;LDL. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;HDL. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;BMI. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: weight with kilograms on a scale,height with meters with the use of a rubber meter.;The severity of fatty liver. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: ultrasound.	—

Measure

Time frame

ALT. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: photometric.;AST. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: photometric.;FBS. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: Fasting blood glucose concentrations.;Triglisirid. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;Cholestrol. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;LDL. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;HDL. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: blood test.;BMI. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: weight with kilograms on a scale,height with meters with the use of a rubber meter.;The severity of fatty liver. Timepoint: before intervention, 1 and 2 months after intervention. Method of measurement: ultrasound.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaral Marzban

Zanjan University of Medical Sciences

maralmarzban46@yahoo.com+98 24 17124

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026